Australia markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.6000+0.0400 (+2.56%)
At close: 04:00PM EDT
1.5300 -0.07 (-4.38%)
Pre-market: 05:02AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5600
Open1.5400
Bid1.6100 x 3200
Ask0.0000 x 2900
Day's range1.5200 - 1.7400
52-week range1.2600 - 8.8700
Volume8,132,846
Avg. volume3,736,445
Market cap142.044M
Beta (5Y monthly)0.25
PE ratio (TTM)N/A
EPS (TTM)-3.6800
Earnings date01 May 2023 - 05 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.55
  • Zacks

    Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock priced at-the-market under Nasdaq rules. Each share of common stock (or common stock equivalent in lieu thereof) wa

  • GlobeNewswire

    Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock in a registered direct offering priced at-the-market under